

Mona M Sabra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1766329/publications.pdf>

Version: 2024-02-01

22
papers

1,147
citations

567281

15
h-index

677142

22
g-index

22
all docs

22
docs citations

22
times ranked

1311
citing authors

#	ARTICLE	IF	CITATIONS
1	Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 1015.	2.2	359
2	Vemurafenib Redifferentiation of <i>BRAF</i> Mutant, RAI-Refractory Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1417-1428.	3.6	165
3	Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. <i>Cancer</i> , 2017, 123, 2955-2964.	4.1	70
4	External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. <i>Journal of Surgical Oncology</i> , 2014, 110, 375-382.	1.7	55
5	Clinical Outcomes Following Empiric Radioiodine Therapy in Patients with Structurally Identifiable Metastatic Follicular Cell-Derived Thyroid Carcinoma with Negative Diagnostic But Positive Post-Therapy ¹³¹ I Whole-Body Scans. <i>Thyroid</i> , 2012, 22, 877-883.	4.5	53
6	Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas. <i>Thyroid</i> , 2016, 26, 1588-1597.	4.5	53
7	Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics. <i>Thyroid</i> , 2017, 27, 632-640.	4.5	52
8	Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 295-305.	4.7	43
9	Time Course and Predictors of Structural Disease Progression in Pulmonary Metastases Arising from Follicular Cell-Derived Thyroid Cancer. <i>Thyroid</i> , 2016, 26, 518-524.	4.5	41
10	AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features. <i>Head and Neck</i> , 2018, 40, 1881-1888.	2.0	41
11	Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: A practical approach to clinical decision making. <i>Oral Oncology</i> , 2013, 49, 676-683.	1.5	37
12	Enhancing Radioiodine Incorporation in <i>BRAF</i> -Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. <i>Thyroid</i> , 2022, 32, 273-282.	4.5	30
13	^{RAI} thyroid bed uptake after total thyroidectomy: A novel ^{SPECT} ^{CT} anatomic classification system. <i>Laryngoscope</i> , 2015, 125, 2417-2424.	2.0	25
14	Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. <i>Thyroid</i> , 2018, 28, 1180-1189.	4.5	23
15	Thyroid Cancer Bone Metastasis. <i>Clinical Nuclear Medicine</i> , 2019, 44, e465-e471.	1.3	22
16	Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies. <i>Thyroid</i> , 2020, 30, 1112-1119.	4.5	15
17	Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy. <i>Clinical Endocrinology</i> , 2019, 90, 617-622.	2.4	14
18	Thyroid Cancer Brain Metastasis. <i>Clinical Nuclear Medicine</i> , 2019, 44, 544-549.	1.3	13

#	ARTICLE	IF	CITATIONS
19	Prevalence of diabetes mellitus in patients with newly evaluated papillary thyroid cancer. <i>Thyroid Research</i> , 2014, 7, 7.	1.5	11
20	Recombinant Human Thyroid-Stimulating Hormone To Stimulate 131-1 Uptake For Remnant Ablation And Adjuvant Therapy. <i>Endocrine Practice</i> , 2013, 19, 149-156.	2.1	9
21	Thyroid Cancer and Telemedicine During the COVID-19 Pandemic. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab059.	0.2	8
22	Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. <i>Cancer</i> , 2021, 127, 4161-4170.	4.1	8